2008
Natural antibodies in murine atherosclerosis.
Binder CJ,
Chou MY,
Fogelstrand L,
Hartvigsen K,
Shaw PX,
Boullier A,
Witztum JL.
Curr Drug Targets. 2008, Mar;9(3):190–5. Review.
2008
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.
Bergmark C,
Dewan A,
Orsoni A,
Merki E,
Miller ER,
Shin MJ,
Binder CJ,
Hörkkö S,
Krauss RM,
Chapman MJ,
Witztum JL,
Tsimikas S.
J Lipid Res. 2008, Oct;49(10):2230–9.
2008
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1–PDGFRalpha.
Baumgartner C,
Gleixner KV,
Peter B,
Ferenc V,
Gruze A,
Remsing Rix LL,
Bennett KL,
Samorapoompichit P,
Lee FY,
Pickl WF,
Esterbauer H,
Sillaber C,
Superti-Furga G,
Valent P.
Exp Hematol, 2008 Oct;36(10):1244–53.
2008
Size does matter: macro ncRNAs and the regulation of imprinted gene clusters.
Stricker SH,
Barlow DP,
Latos PA.
European Pharmaceutical Review 2008, Issue 1,10–17.
2008
Analysis of cellular protein complexes by affinity purification and mass spectrometry.
Bürckstümmer T,
Bennett KL.
In Proteomics Methods Express 2008 (O’Connor CD and Hames BD, eds.), pp 119–134, Scion, Oxfordshire.
2007
Selective serotonin reuptake inhibitors – A new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol.
Schuster C,
Fernbach N,
Rix U,
Superti-Furga G,
Holy M,
Freissmuth M,
Sitte HH,
Sexl V.
2007, 74(9):1424–35.
2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets.
Rix U,
Hantschel O,
Dürnberger G,
Remsing Rix LL,
Planyavsky M,
Fernbach NV,
Kaupe I,
Bennett KL,
Valent P,
Colinge J,
Köcher T,
Superti-Furga G.
Blood. 2007, 110:4055–4063.
2007
Assessing peptide de novo sequencing algorithms performance on large and diverse data sets.
Pitzer E,
Masselot A,
Colinge J.
Proteomics 2007, 7:3051–3054.
2007
Silencing by imprinted noncoding RNAs: is transcription the answer? Trends Genet.
Pauler FM,
Koerner MV,
Barlow DP.
2007, 23(6):284–92.
2007
The minimum information required for reporting a molecular interaction experiment (MIMIx).
Orchard S,
Salwinski L,
Kerrien S,
Montecchi- Palazzi L,
Oesterheld M,
Stumpflen V,
Ceol A,
Chatr-aryamontri A,
Armstrong J,
Woollard P,
Salama JJ,
Moore S,
Wojcik J,
Bader GD,
Vidal M,
Cusick ME,
Gerstein M,
Gavin AC,
Superti-Furga G,
et al.
Nat Biotechnol. 2007, 25(8):894–8.
